Cargando…
Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma
INTRODUCTION: Large cell neuroendocrine carcinoma (LCNEC) is a rare and highly aggressive high-grade neuroendocrine neoplasm, which can arise from anywhere in the body. Due to its rarity there is a lacuna in our understanding of LCNEC’s molecular biology. In 2016, Rekhtman and colleagues presented o...
Autores principales: | Saghaeiannejad Esfahani, Hoda, Vela, Cory M., Chauhan, Aman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203494/ https://www.ncbi.nlm.nih.gov/pubmed/34141612 http://dx.doi.org/10.3389/fonc.2021.653153 |
Ejemplares similares
-
Management of Large Cell Neuroendocrine Carcinoma
por: Corbett, Virginia, et al.
Publicado: (2021) -
Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
por: Li, Yanong, et al.
Publicado: (2021) -
A Pan-Cancer Assessment of RB1/TP53 Co-Mutations
por: Cai, Ling, et al.
Publicado: (2022) -
Impact of Low-Burden TP53 Mutations in the Management of CLL
por: Lazarian, Gregory, et al.
Publicado: (2022) -
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
por: Catherwood, Mark A., et al.
Publicado: (2022)